Johnson & Johnson Announces Collaboration to Expand Manufacturing Capabilities For its COVID-19 Vaccine Candidate in Support of the Company’s Goal to Supply More Than One Billion Vaccine Doses Globally

Company Signs Agreement with Emergent BioSolutions in the U.S. As Part of its Investment

First in Series of Anticipated Strategic Collaborations Designed to Further the Company’s Goal of Ensuring Global Supply of a Safe and Effective Vaccine for COVID-19Continue reading

Pathogen and Microbiome Institute at NAU to test the antiviral activity of 2X-121, a Danish Company’s PARP inhibitor, against Coronavirus

Hørsholm, Denmark (April 22nd, 2020) – Oncology Venture A/S (“OV” or the Company) today announced that it has entered into an agreement with the Pathogen and Microbiome Institute at Northern Arizona University (NAU) to test the antiviral activity of 2X-121, its PARP inhibitor, against Coronavirus.Continue reading

Accelerate Diagnostics and BioCheck Announce Commercial Supply and Collaboration Agreement to Distribute MS-FAST Chemiluminescence Immunoassay Analyzer and SARS-CoV-2 Antibody Tests

TUCSON, Ariz., — Accelerate Diagnostics, Inc. (NASDAQ:AXDX) and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that they have entered into a commercial supply and collaboration agreement. Under the agreement, Accelerate Diagnostics will distribute the BioCheck MS-FAST, a fully-automated chemiluminescence immunoassay analyzer, along with BioCheck’s SARS-CoV-2 tests for the detection of IgG and IgM antibodies. The agreement covers North America, Europe and the Middle East.

Continue reading

Novel coronavirus detected, monitored in wastewater

Within weeks of arriving on the world stage, SARS-CoV-2 has managed to encircle the globe, leaving illness, mortality and economic devastation in its vast wake. One of the central challenges facing health authorities and the medical community has been testing for the elusive virus on a sufficiently comprehensive scale.

A new approach to monitoring the novel coronavirus, (as well as other dangerous pathogens and chemical agents), is being developed and refined. Known as wastewater-based epidemiology (WBE), the method mines sewage samples for vital clues about human health. It can potentially identify levels of coronavirus infection at both a local and global scale.Continue reading

Quest Diagnostics Begins to Perform COVID-19 Antibody Testing

SECAUCUS, N.J., April 21, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it has begun to perform antibody testing for coronavirus (COVID-19) using blood samples. With the new service, Quest Diagnostics now provides healthcare providers in the United States access to COVID-19 antibody as well as molecular diagnostic laboratory testing.  Continue reading

GenoSensor Granted FDA Emergency Use Authorization for High Throughput COVID-19 RT-PCR Diagnostic for Use in U.S.

 

  • FDA Emergency Use Authorization for the GSTM COVID-19 RT-PCR KIT was issued on April 16, 2020. View FDA Letter: https://www.fda.gov/media/137090/download
  • With a high sensitivity detection (single copy detection) when run according to its instructions for use in a qualified clinical lab, the GSTM COVID-19 RT-PCR test, is one of the most sensitive tests currently available under an FDA Emergency Use Authorization.
  • GSTM COVID-19 RT-PCR KIT runs on the Applied Biosystems™ 7500 Fast Dx Real-Time PCR Instrument. Kits are available for the 96 well plate (22 clinical samples) and 384 well plate (94 clinical samples) and provides test results in less than 90 minutes.
  • The GSTM COVID-19 RT-PCR KIT is intended for use by trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures. Instructions for use, the FDA EUA letter, and other documentation is provided at GenoSensorCorp.com.

Continue reading

UArizona Launches Two-Way Texting System to Gather and Provide Critical COVID-19 Health Data

TUCSON, Ariz. – Designed to address a critical lack of local data as the COVID-19 pandemic continues to spread, a University of Arizona team of researchers from UArizona Health Sciences and the Data Science Institute is launching a two-way texting system to gather and provide valuable information to track the COVID-19 pandemic in Arizona and identify areas where more resources may be needed.

 

Continue reading

Identifying Critical Infrastructure During COVID-19

The Department of Homeland Security the CISA guidelines on essential critical infrastructure. The guideline has been updated from:

 “Workers conducting research critical to COVID-19 response” to  “Workers, including lab personnel who perform critical biomedical research, development, and testing, needed for COVID-19 response or other diseases”.

Learn more at: https://www.cisa.gov/identifying-critical-infrastructure-during-covid-19

Continue reading